Cellectar Biosciences‘ public offering raised $8 million, the company announced today.

“We are pleased with the results of this offering, including the underwriter’s exercise of their full over-allotment option,” Cellectar Biosciences President and CEO Jim Caruso said in a statement. “Successfully raising over $8 million positions the company to execute our operating plan to achieve a number of meaningful milestones.”

According to a release, the company issued approximately 3.78 million Series A warrants with an exercise price of $3.04 per share.

Cellectar Biosciences has now completed a secondary stock offering of stocks and warrants with the funds to boost development of cancer-curing drugs.